Quantitative analysis of bone marrow CD34 cells in aplastic anemia and hypoplastic myelodysplastic syndromes

Research output: Contribution to journalArticle

Abstract

Aplastic anemia (AA) and hypoplastic myelodysplastic syndromes (hMDS) are often difficult to distinguish. However, an accurate diagnosis is important because the prognosis and treatment of these diseases may differ. CD34+ hematopoietic progenitors are central to the pathogenesis of both disorders; they are the targets of the autoimmune attack in AA and neoplastic transformation in MDS. The aim of this study was to assess whether bone marrow CD34+ cell numbers could be used in differentiating between AA and hMDS. The percentage of bone marrow CD34+ cells was normal or increased (mean -3.5+0.5%, range 1-7%) in 15 of 35 patients studied, and low (mean -0.13±0.02%, range 0.02-0.36%) in 20 of 35 patients. All patients with a normal or increased percentage of CD34+ cells were ultimately diagnosed with hMDS based on the detection of clonal cytogenetic abnormalities or progression to refractory anemia with excess blasts/acute myeloid leukemia. All patients with low marrow CD34+ cell numbers met standard clinical criteria for AA and have not demonstrated neoplastic transformation with follow-up. Quantification of marrow CD34+ cells may serve as an important tool for distinguishing between AA and hMDS.

Original languageEnglish (US)
Pages (from-to)458-462
Number of pages5
JournalLeukemia
Volume20
Issue number3
DOIs
StatePublished - Mar 2006

Fingerprint

Aplastic Anemia
Myelodysplastic Syndromes
Bone Marrow Cells
Cell Count
Bone Marrow
Refractory Anemia with Excess of Blasts
Acute Myeloid Leukemia
Chromosome Aberrations

Keywords

  • Aplastic anemia
  • CD34
  • Hypoplastic myelodysplastic syndrome
  • Pancytopenia

ASJC Scopus subject areas

  • Hematology
  • Cancer Research

Cite this

@article{0e3161e8239f4e5db1187a6af3bc9a7a,
title = "Quantitative analysis of bone marrow CD34 cells in aplastic anemia and hypoplastic myelodysplastic syndromes",
abstract = "Aplastic anemia (AA) and hypoplastic myelodysplastic syndromes (hMDS) are often difficult to distinguish. However, an accurate diagnosis is important because the prognosis and treatment of these diseases may differ. CD34+ hematopoietic progenitors are central to the pathogenesis of both disorders; they are the targets of the autoimmune attack in AA and neoplastic transformation in MDS. The aim of this study was to assess whether bone marrow CD34+ cell numbers could be used in differentiating between AA and hMDS. The percentage of bone marrow CD34+ cells was normal or increased (mean -3.5+0.5{\%}, range 1-7{\%}) in 15 of 35 patients studied, and low (mean -0.13±0.02{\%}, range 0.02-0.36{\%}) in 20 of 35 patients. All patients with a normal or increased percentage of CD34+ cells were ultimately diagnosed with hMDS based on the detection of clonal cytogenetic abnormalities or progression to refractory anemia with excess blasts/acute myeloid leukemia. All patients with low marrow CD34+ cell numbers met standard clinical criteria for AA and have not demonstrated neoplastic transformation with follow-up. Quantification of marrow CD34+ cells may serve as an important tool for distinguishing between AA and hMDS.",
keywords = "Aplastic anemia, CD34, Hypoplastic myelodysplastic syndrome, Pancytopenia",
author = "Matsui, {W. H.} and Brodsky, {Robert A} and Smith, {B Douglas} and Borowitz, {Michael J} and Jones, {Richard J}",
year = "2006",
month = "3",
doi = "10.1038/sj.leu.2404119",
language = "English (US)",
volume = "20",
pages = "458--462",
journal = "Leukemia",
issn = "0887-6924",
publisher = "Nature Publishing Group",
number = "3",

}

TY - JOUR

T1 - Quantitative analysis of bone marrow CD34 cells in aplastic anemia and hypoplastic myelodysplastic syndromes

AU - Matsui, W. H.

AU - Brodsky, Robert A

AU - Smith, B Douglas

AU - Borowitz, Michael J

AU - Jones, Richard J

PY - 2006/3

Y1 - 2006/3

N2 - Aplastic anemia (AA) and hypoplastic myelodysplastic syndromes (hMDS) are often difficult to distinguish. However, an accurate diagnosis is important because the prognosis and treatment of these diseases may differ. CD34+ hematopoietic progenitors are central to the pathogenesis of both disorders; they are the targets of the autoimmune attack in AA and neoplastic transformation in MDS. The aim of this study was to assess whether bone marrow CD34+ cell numbers could be used in differentiating between AA and hMDS. The percentage of bone marrow CD34+ cells was normal or increased (mean -3.5+0.5%, range 1-7%) in 15 of 35 patients studied, and low (mean -0.13±0.02%, range 0.02-0.36%) in 20 of 35 patients. All patients with a normal or increased percentage of CD34+ cells were ultimately diagnosed with hMDS based on the detection of clonal cytogenetic abnormalities or progression to refractory anemia with excess blasts/acute myeloid leukemia. All patients with low marrow CD34+ cell numbers met standard clinical criteria for AA and have not demonstrated neoplastic transformation with follow-up. Quantification of marrow CD34+ cells may serve as an important tool for distinguishing between AA and hMDS.

AB - Aplastic anemia (AA) and hypoplastic myelodysplastic syndromes (hMDS) are often difficult to distinguish. However, an accurate diagnosis is important because the prognosis and treatment of these diseases may differ. CD34+ hematopoietic progenitors are central to the pathogenesis of both disorders; they are the targets of the autoimmune attack in AA and neoplastic transformation in MDS. The aim of this study was to assess whether bone marrow CD34+ cell numbers could be used in differentiating between AA and hMDS. The percentage of bone marrow CD34+ cells was normal or increased (mean -3.5+0.5%, range 1-7%) in 15 of 35 patients studied, and low (mean -0.13±0.02%, range 0.02-0.36%) in 20 of 35 patients. All patients with a normal or increased percentage of CD34+ cells were ultimately diagnosed with hMDS based on the detection of clonal cytogenetic abnormalities or progression to refractory anemia with excess blasts/acute myeloid leukemia. All patients with low marrow CD34+ cell numbers met standard clinical criteria for AA and have not demonstrated neoplastic transformation with follow-up. Quantification of marrow CD34+ cells may serve as an important tool for distinguishing between AA and hMDS.

KW - Aplastic anemia

KW - CD34

KW - Hypoplastic myelodysplastic syndrome

KW - Pancytopenia

UR - http://www.scopus.com/inward/record.url?scp=33644505823&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33644505823&partnerID=8YFLogxK

U2 - 10.1038/sj.leu.2404119

DO - 10.1038/sj.leu.2404119

M3 - Article

C2 - 16437138

AN - SCOPUS:33644505823

VL - 20

SP - 458

EP - 462

JO - Leukemia

JF - Leukemia

SN - 0887-6924

IS - 3

ER -